BVS Earnings Date: Nov 2, 2026 (Estimated) — Bioventus Inc.

NASDAQ · Healthcare · Medical Devices

Updated Oct 30, 2026

Price $14.12

Market Cap $964.5M

P/E 18.6

52W Range $6.47 – $15.89

Next Earnings Nov 2, 2026 · Before open (est.)

When is BVS's next earnings date?

Bioventus Inc. (BVS) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.15 on revenue of $149.5M.

How did BVS do in its last earnings report?

In its most recent report on Aug 5, 2026 (Q2 2026), Bioventus Inc. posted EPS of $0.22 versus the $0.22 estimate, a beat of 4.8%. Revenue was $153.2M against a $155.4M estimate. The stock's 1-day post-earnings move was +13.7%.

How much does BVS stock move after earnings?

BVS beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 15.8% (up or down) in the day after earnings.

About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Earnings History

Date	Period	EPS Est.	EPS Act.	Surprise	Revenue	Result	1D Δ	1W Δ	1M Δ
2026-08-05	Q2 2026	0.22	0.22	+4.76%	$153.2M	✅ Beat	+13.71%	+3.20%	+7.08%
2026-05-06	Q1 2026	0.07	0.15	+114.29%	$132.1M	✅ Beat	+2.25%	-5.06%	-18.54%
2026-03-05	Q4 2025	0.22	0.24	+9.09%	$157.9M	✅ Beat	+7.44%	+5.08%	+5.90%
2025-11-04	Q3 2025	0.12	0.15	+25.00%	$138.7M	✅ Beat	+15.09%	+14.18%	+15.40%
2025-08-06	Q2 2025	0.21	0.21	+0.00%	$147.7M	➖ Inline	+18.73%	+19.06%	+15.64%
2025-03-11	Q4 2024	0.08	0.15	+87.50%	$153.6M	✅ Beat	+23.29%	+11.87%	-12.67%
2024-11-05	Q3 2024	0.03	0.06	+100.00%	$139.0M	✅ Beat	-16.27%	-9.26%	-19.47%
2024-08-06	Q2 2024	0.07	0.19	+171.43%	$151.2M	✅ Beat	+29.23%	+20.77%	+54.31%